Tris Pharma

Tris Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. Our focus is on the development and commercialization of innovative medicines that address unmet patient needs and we have more than 150 U.S. and International patents including applications. We market several branded and generic products in the U.S; license our products in the U.S. and international markets and we have a robust pipeline of innovative products, that employ our proprietary science and technology, to meet patients’ needs in neuroscience and other therapeutic categories. Our science and technology make us unique, but it is our team members that set us apart; they are the engine that fuels Tris’ passion and innovation. The Tris team comprises of approximately 500 diverse individuals; one third of whom operate in the field throughout the U.S. while the other two-thirds work from Tris’ NJ operations. Tris colleagues understand the criticality of operating a successful business and take pride in the company’s success. But of equal importance to each member of the team is how we interact with one another on a daily basis. We believe in each other and we believe in respectful, open and honest communications to help support individual and team success. At Tris, we strive to ensure our field and home office teams are connected and engaged. We listen to our teams in numerous ways, including through our Diversity & Inclusion Committee and our Women’s Business Council, to help ensure every employee’s voice is heard. After all, it is our daily interactions with one another that build and sustain our culture, which fuels our growth.

Company Details

Employees
464
Founded
-
Address
2031 Us-130, Monmouth Junction,new Jersey 08852,united States
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Monmouth Junction, New Jersey
Looking for a particular Tris Pharma employee's phone or email?

Tris Pharma Questions

News

Tris Pharma Announces Acceptance of New Review Article Highlighting Challenges of Treating Moderate-to-Severe Acute Pain with Currently Available Drugs - Yahoo Finance

Tris Pharma Announces Acceptance of New Review Article Highlighting Challenges of Treating Moderate-to-Severe Acute Pain with Currently Available Drugs Yahoo Finance

Tris Pharma to Unveil Positive Phase 3 Results including a Strong Safety Profile Showcasing the Potential of Cebranopadol, an Investigational First-in-Class Dual-NMR Agonist for the Treatment of Pain, at the 2025 ASRA Annual Meeting - Business Wire

Tris Pharma to Unveil Positive Phase 3 Results including a Strong Safety Profile Showcasing the Potential of Cebranopadol, an Investigational First-in-Class Dual-NMR Agonist for the Treatment of Pain, at the 2025 ASRA Annual Meeting Business Wire

Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain - Business Wire

Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain Business Wire

Pulse Health partners with Tris Pharma to Power Omnichannel HCP Engagement for ADHD Products - PR Newswire

Pulse Health partners with Tris Pharma to Power Omnichannel HCP Engagement for ADHD Products PR Newswire

Tris Pharma Promotes Manesh Naidu to Chief Commercial Officer - citybiz

Tris Pharma Promotes Manesh Naidu to Chief Commercial Officer citybiz

July 2024: Pharmacy Product News - Pharmacy Times

July 2024: Pharmacy Product News Pharmacy Times

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain - Business Wire

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain Business Wire

Tris Pharma Secures Additional ex-US Approvals to Expand Global Availability of Quillivant XR and QuilliChew ER for the Treatment of Attention Deficit Hyperactivity Disorder - Yahoo Finance

Tris Pharma Secures Additional ex-US Approvals to Expand Global Availability of Quillivant XR and QuilliChew ER for the Treatment of Attention Deficit Hyperactivity Disorder Yahoo Finance

Tris Pharma Appoints Franchesca Fowler as Chief Compliance Officer and Vice President - citybiz

Tris Pharma Appoints Franchesca Fowler as Chief Compliance Officer and Vice President citybiz

Tris Pharma Issues Voluntary Nationwide Recall of Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen - PR Newswire

Tris Pharma Issues Voluntary Nationwide Recall of Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen PR Newswire

Tris Pharma Expands Leadership Team - citybiz

Tris Pharma Expands Leadership Team citybiz

Findings Presented at PAINWeek 2024 Demonstrate Tris Pharma’s Investigational, First-in-Class Therapy Cebranopadol Provides Potent, Prolonged Pain Relief with Improved Safety Over Oxycodone - Business Wire

Findings Presented at PAINWeek 2024 Demonstrate Tris Pharma’s Investigational, First-in-Class Therapy Cebranopadol Provides Potent, Prolonged Pain Relief with Improved Safety Over Oxycodone Business Wire

Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD - Business Wire

Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD Business Wire

Tris Pharma Initiates ALLEVIATE-1 and ALLEVIATE-2, Pivotal Phase 3 Trials Investigating Cebranopadol, a First-in-Class Compound with a Novel Mechanism of Action to Treat Pain - Business Wire

Tris Pharma Initiates ALLEVIATE-1 and ALLEVIATE-2, Pivotal Phase 3 Trials Investigating Cebranopadol, a First-in-Class Compound with a Novel Mechanism of Action to Treat Pain Business Wire

Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder - Business Wire

Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder Business Wire

Tris Pharma’s Once-Daily ADHD Medication, ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, Now Available in the United States - Business Wire

Tris Pharma’s Once-Daily ADHD Medication, ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, Now Available in the United States Business Wire

Cranbury Pharmaceuticals Receives U.S. FDA Approval for First Generic Version of Emflaza - Business Wire

Cranbury Pharmaceuticals Receives U.S. FDA Approval for First Generic Version of Emflaza Business Wire

Tris Digital Health Forms, Will Focus on Digital Diagnostic Platform for ADHD - Psychiatric Times

Tris Digital Health Forms, Will Focus on Digital Diagnostic Platform for ADHD Psychiatric Times

FDA Approves Tris Pharma’s Onyda XR, a Once-Daily, Extended-Release Oral Suspension for the Treatment of ADHD - Pharmaceutical Executive

FDA Approves Tris Pharma’s Onyda XR, a Once-Daily, Extended-Release Oral Suspension for the Treatment of ADHD Pharmaceutical Executive

Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial - Applied Clinical Trials

Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial Applied Clinical Trials

Tris Pharma Records Late-Stage Win for Non-Opioid Painkiller - BioSpace

Tris Pharma Records Late-Stage Win for Non-Opioid Painkiller BioSpace

Infants' Ibuprofen recalled due to potentially higher concentrations of Ibuprofen - FOX 32 Chicago

Infants' Ibuprofen recalled due to potentially higher concentrations of Ibuprofen FOX 32 Chicago

More Ibuprofen Oral Susp Lots Recalled Due to Higher Concentration - Medical Professionals Reference

More Ibuprofen Oral Susp Lots Recalled Due to Higher Concentration Medical Professionals Reference

FDA Approves Cranbury’s Generic Version of Deflazacort to Treat Duchenne Muscular Dystrophy - NeurologyLive

FDA Approves Cranbury’s Generic Version of Deflazacort to Treat Duchenne Muscular Dystrophy NeurologyLive

Tris Pharma Awarded Up to $16.6M to Advance Treatment for Opioid Use Disorder - New Jersey Business Magazine

Tris Pharma Awarded Up to $16.6M to Advance Treatment for Opioid Use Disorder New Jersey Business Magazine

Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of Amphetamine Extended-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder - Psychiatrist.com

Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of Amphetamine Extended-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder Psychiatrist.com

Extended-Release Liquid Amphetamine for ADHD Now Available - Medical Professionals Reference

Extended-Release Liquid Amphetamine for ADHD Now Available Medical Professionals Reference

Tris Pharma Announces the Launch of DYANAVEL™ XR (amphetamine) Extended-release Oral Suspension, CII for the Treatment of Children with ADHD - PR Newswire

Tris Pharma Announces the Launch of DYANAVEL™ XR (amphetamine) Extended-release Oral Suspension, CII for the Treatment of Children with ADHD PR Newswire

Childrens’ Pain Reliever Recalled Due to Potentially Higher Potency Level - Medical Professionals Reference

Childrens’ Pain Reliever Recalled Due to Potentially Higher Potency Level Medical Professionals Reference

FDA Approves Onyda XR, First and Only Liquid Nonstimulant for ADHD - Drug Topics

FDA Approves Onyda XR, First and Only Liquid Nonstimulant for ADHD Drug Topics

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Oral Suspension for the Treatment of Children With ADHD - PR Newswire Canada

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Oral Suspension for the Treatment of Children With ADHD PR Newswire Canada

Perrigo and Tris Pharma Launch Store Brand Version of Delsym - CBS News

Perrigo and Tris Pharma Launch Store Brand Version of Delsym CBS News

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Chewable Tablets for the Treatment of Children With ADHD - PR Newswire Canada

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Chewable Tablets for the Treatment of Children With ADHD PR Newswire Canada

Should You Add an Executive Summary for Resumes, And, If So, What Should It Say? - BioSpace

Should You Add an Executive Summary for Resumes, And, If So, What Should It Say? BioSpace

Top Tris Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant